International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8053631
Original Article
Prognostic Evaluation of Frailty Index in Hospitalized Moderate to Severe COVID 19 Geriatric Patients
 ,
 ,
 ,
 ,
 ,
 ,
Published
June 19, 2023
Abstract
Background: Elderly people are particularly affected by COVID -19. Elderly people who suffered from other diseases and were frail were particularly likely to develop severe COVID -19 or die from the infection. The aim of the current study is to assess the frailty index in COVID -19 geriatric patients admitted to hospital using the Clinical Frailty Scale and the FI -Lab21 and to establish a relationship between frailty and outcome prediction. Methods: In a prospective observational study we conducted, we assessed the clinical presentation and frailty-related characteristics of hospitalised individuals aged > 65 years with positive moderate-severe COVID -19 pneumonia. The Clinical Frailty Scale (CFS) and FI Lab-21 criteria were used to assess frailty at the time of admission. Mortality and change in CFS score from admission to discharge were recorded. Results: The age of patients participating in the study COVID -19 ranged from 65 to 90 years, and the mean age was 72.14±6.13 years. Men predominated in the study population (73.0%). Using the Clinical Frailty Scale (CFS), 21.0% of patients were not frail (score 1-3), 46.0% were mildly to moderately frail (score 5-6), and 33.0% were severely frail (score 7-8). Among the frail patients, the severely frail cases (based on CFS) were significantly older than the mild-to-moderate and nonfrail COVID -19 cases. The mortality rate was significantly higher in severely frail (66.7%) and mild-to-moderately frail (45.7%) patients than in nonfrail (28.6%) patients. Conclusion: The results show that the clinical frailty scale has no significant association with FILab-21 in COVID -19 cases. CFS showed a significant association with disease progression in COVID -19 cases.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
958 Views
164 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved